Nirav Desai
Research Subjects
Nirav Desai has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Akruti Naik
D-UIAS AND D-SIM&C
2 shared publications - Amol M. Patel
Department of Internal Medicine, Houston Methodist Hospital, Houston, TX, USA
1 shared publication - Ariel Brautbar
Pediatric Endocrinology and Diabetes, Cook Children's Medical Center, Fort Worth, TX; Department of Genetics, Cook Children's Medical Center, Fort Worth, TX
1 shared publication - Don P. Wilson
Department of Pediatric Endocrinology and Diabetes, Cook Children's Medical Center, Fort Worth, TX, USA (Dr Wilson)
1 shared publication - Hetal R.Thaker
Atmiya University
1 shared publication N. N. Rege
Department of Gastroenterology Surgical Services Parel Bombay 400 012 India
1 shared publication
Latest Publications
- 1 January 2022
- Published by Springer Nature
- p. 669-683
Creation and Segmentation of Image Dataset of Mung Bean Plant Leaf
- 1 January 2022
- Published by Springer Nature
- p. 669-683
Creation and Segmentation of Image Dataset of Mung Bean Plant Leaf
- 1 May 2016
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 10 (3) , 650-653
Severe hypercholesterolemia and liver disease in a 3-year old
- 1 May 2016
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 10 (3) , 650-653
Severe hypercholesterolemia and liver disease in a 3-year old
- Open Access
- 1 January 1995
- Published by Wiley in HPB Surgery
- Vol. 9 (1) , 5-11
Can We Do Away With PTBD?
Percutaneous Transhepatic Biliary Drainage (PTBD) is performed in surgical jaundice to decompress the biliary tree and improve hepatic functions. However, the risk of sepsis is high in these patients due to immunosuppression and surgical outcome remains poor. This raises a question—can we do away with PTBD? To answer this query a study was carried out in 4 groups of patients bearing in mind the high incidence of sepsis and our earlier studies, which have demonstrated immunotherapeutic potential of Tinospora cordifolia (TC): (A) those undergoing surgery without PTBD (n = 14), (B) those undergoing surgery after PTBD (n = 13). The mortality was 57.14% in Group A as compared to 61.54% in Group B. Serial estimations of bilirubin levels carried out during the course of drainage (3 Wks) revealed a gradual and significant decrease from 12.52 ± 8.3 mg% to 5.85 ± 3.0 mg%. Antipyrine half‐life did not change significantly (18.35 ± 4.2 hrs compared to basal values 21.96 ± 3.78 hrs). The phagocytic and intracellular killing (ICK) capacities of PMN remained suppressed (Basal: 22.13 ± 3.68% phago, and 19.1 ± 4.49% ICK; Post drainage: 20 ± 8.48% Phago and 11.15 ± 3.05% ICK). Thus PTBD did not improve the metabolic capacity ofthe liver and mortality was higher due to sepsis. Group (C) patientg received TC during PTBD (n = 16) and Group (D) patients received TC without PTBD (n = 14). A significant improvement in PMN functions occurred by 3 weeks in both groups (30.29 ± 4.68% phago, 30 ± 4.84% ICK in Group C and 30.4 ± 2.99% phago, 27.15 ± 6.19% ICK in Group D). The mortality in Groups C and D was 25% and 14.2% respectively during the preoperative period. There was no mortality after surgery. It appears from this study that host defenses as reflected by PMN functions play an important role in influencing prognosis. Further decompression of the biliary tree by PTBD seems unwarranted.
- 1 January 1995
- Published by Wiley in HPB Surgery
- Vol. 9 (1) , 5-11
Open AccessCan We Do Away With PTBD?
Percutaneous Transhepatic Biliary Drainage (PTBD) is performed in surgical jaundice to decompress the biliary tree and improve hepatic functions. However, the risk of sepsis is high in these patients due to immunosuppression and surgical outcome remains poor. This raises a question—can we do away with PTBD? To answer this query a study was carried out in 4 groups of patients bearing in mind the high incidence of sepsis and our earlier studies, which have demonstrated immunotherapeutic potential of Tinospora cordifolia (TC): (A) those undergoing surgery without PTBD (n = 14), (B) those undergoing surgery after PTBD (n = 13). The mortality was 57.14% in Group A as compared to 61.54% in Group B. Serial estimations of bilirubin levels carried out during the course of drainage (3 Wks) revealed a gradual and significant decrease from 12.52 ± 8.3 mg% to 5.85 ± 3.0 mg%. Antipyrine half‐life did not change significantly (18.35 ± 4.2 hrs compared to basal values 21.96 ± 3.78 hrs). The phagocytic and intracellular killing (ICK) capacities of PMN remained suppressed (Basal: 22.13 ± 3.68% phago, and 19.1 ± 4.49% ICK; Post drainage: 20 ± 8.48% Phago and 11.15 ± 3.05% ICK). Thus PTBD did not improve the metabolic capacity ofthe liver and mortality was higher due to sepsis. Group (C) patientg received TC during PTBD (n = 16) and Group (D) patients received TC without PTBD (n = 14). A significant improvement in PMN functions occurred by 3 weeks in both groups (30.29 ± 4.68% phago, 30 ± 4.84% ICK in Group C and 30.4 ± 2.99% phago, 27.15 ± 6.19% ICK in Group D). The mortality in Groups C and D was 25% and 14.2% respectively during the preoperative period. There was no mortality after surgery. It appears from this study that host defenses as reflected by PMN functions play an important role in influencing prognosis. Further decompression of the biliary tree by PTBD seems unwarranted.